Could Artificial Sweeteners Alter Your Microbiome?
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Jan. 3, 2024 -- You may think that artificial sweeteners can help you lose some weight, but a new study finds they are no good for your gut’s microbiome.
People who use aspartame (Equal), sucralose (Splenda), saccharin (Sweet’N Low), or stevia leaf extract tended to have intestinal bacteria colonies that differed significantly from those of people who didn’t use sugar substitutes, researchers found.
They had less rich colonies of bacteria in their small intestines or, even worse, higher levels of bacteria that churn out harmful toxins.
“Artificial sweeteners are not benign for the microbiome of the gut,” said study author Dr. Ruchi Mathur, a professor and endocrinologist with Cedars-Sinai Medical Center in Los Angeles.
More than 140 million Americans use artificial sweeteners to lower their sugar intake, researchers said in background notes.
However, concerns have been raised that sugar substitutes don’t help with long-term weight loss and might be tied to increased risk of type 2 diabetes and heart disease, researchers said.
The gut microbiome plays a key role in a person’s health, and diet can influence the makeup of these bacteria in significant ways.
So, in a controlled study, researchers analyzed the microbial diversity of the small intestines in people who used artificial sweeteners, including nine who used aspartame and 35 who used other sugar substitutes.
They compared the gut microbiome of those patients to a group of 55 people who didn’t use artificial sweeteners.
“We found that the richness of the bacteria in the small bowel was less in those subjects consuming non-aspartame non-sugar sweeteners when compared to controls, whereas bacterial richness in those consuming aspartame was similar to controls,” Mathur said.
However, that didn’t mean that aspartame users were better off. Their microbiomes were more likely to churn out a toxin called cylindrospermopsin, Mathur said.
“This pathway is recognized for its harmful effects on the liver and the nervous system, and it is classed as a potential cancer-causing agent,” Mathur said.
Future studies should look more closely at how the changes observed here might affect a person’s overall health, researchers said.
The study was published recently in the journal iScience.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-03 22:15
Read more
- Late-Life Menopause Linked to Higher Asthma Risk
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
- First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
- Micronized Amnion/Chorion Aids Interstitial Cystitis/Bladder Pain Syndrome
- 2011 to 2022 Saw Increase in Autism Diagnoses Among Children, Adults
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions